ANAB: The EPS Is Tax Accounting. The Value Is the Royalty Contract.

The 60-second read

Five things to know

1. Royalties are growing. H1 Jemperli sales rose 30.3%, pushing Anaptys toward higher contractual tiers.
2. The profit headline is misleading. Q2 pretax loss became a large profit only after a $181.491M tax benefit.
3. Sagard still gets paid first. About $302.5M had been earned; management estimates paydown in H2 2027.
4. The contract is in court. Trial is complete, the October 20 hearing remains ahead and the remedy is unresolved.
5. The cash narrative does not reconcile. Audited operating outflows total $52.559M, not the release's $72.9M sentence.

Three scenarios, one probability-weighted number

Analyst scenarios in USD per share; no scenario is a court or regulatory forecast.

Signposts: what would change our mind

This is the first Charged Alpha packet for ANAB. Thresholds grade future evidence; they are analytical tests, not company promises.

The market snapshot

ANAB closed at $54.99 on September 21, down 0.39% from the prior close. The print's release-session label is unverified, so this close is not presented as a clean post-earnings reaction baseline. Volume was 524,361 shares. The stock has traveled from a 52-week low of $13.66 to a high of $72.36; a one-day move cannot summarize the value of a royalty stream whose decisive cash flows sit years ahead.

The denominator matters. The June filing reports 29.728M common shares outstanding. At the saved close, that implies approximately $1,634.7M of equity. The provider's $1,628.1M market-cap field uses a slightly different share count, so the primary figure controls our valuation. The gap is not a trading signal; it is a reminder that per-share analysis begins with the current legal ownership count.

The price chart is descriptive. It captures completed closes and marks today's filing date. The April spin-off, royalty news, clinical updates and broad biotechnology sentiment all affected the path. We do not assign every move to earnings. The next sections separate what the statements prove from what the market already appears to expect.

The quarter and transition-period print

The current release contains two different reporting lenses. The quarter covers April through June. The transition period covers January through June because Anaptys changed its fiscal year end from December 31 to June 30. A clean comparison therefore uses Q2 2026 against Q2 2025 and H1 2026 against H1 2025; the audited 10-KT's main table also shows full-year 2025 and 2024 columns, which must not be mislabeled as six-month comparisons.

Q2 collaboration revenue rose to $27.488M from $22.263M, a computed 23.5% increase. H1 revenue rose 6.0% to $53.044M. That is real royalty growth, but the economic quality differs from an ordinary product company: Anaptys licenses the products and collects collaboration economics while GSK and Vanda control commercialization.

The reported EPS is unusable as a shorthand for operating momentum. Q2 diluted net income was $5.11 per share, yet continuing operations lost $-4.174M before tax. A $181.491M tax benefit created most of the accounting profit. The benefit followed release of a deferred-tax-asset valuation allowance after the separation. It is not a recurring royalty margin and cannot be annualized.

FMP's September 21 row reports negative EPS and $26.68M of revenue. Both conflict with the issuer's Q2 table, so this packet rejects those provider actuals. Primary statements control the print.

The royalty engine and its claims

Anaptys is now a royalty-management company. First Tracks holds the former drug-development portfolio after the April 20 spin-off. The continuing business centers on Jemperli with GSK and Quimilza with Vanda. That structure lowers direct clinical spending, but it also concentrates value in contracts, counterparties, patent rights and legal interpretation.

GSK reported $644.1M of Jemperli global net sales in H1 2026, versus $494.3M a year earlier, a computed 30.3% gain. The underlying royalty schedule is 8% below $1B of annual sales, 12% from $1B to $1.5B, 20% from $1.5B to $2.5B and 25% above $2.5B. Those tiers make growth disproportionately valuable once annual sales cross thresholds.

Shareholders do not yet receive all those royalties. Anaptys sold future Jemperli receipts to Sagard for $300M in two transactions. The obligation ends after Sagard receives $600M by March 31, 2031, or $675M later. The 10-KT says Sagard had earned about $302.5M by June 30, while the release estimates roughly $301M and about $299M remaining. We preserve the filing's more exact earned figure and management's approximate remaining-paydown outlook rather than forcing false precision between documents.

Quimilza adds a smaller second engine. Its FDA target action date is December 12, 2026. Approval would matter, but a regulatory date is not revenue. Vanda controls commercialization, and any milestone or royalty must still be earned under the contract.

Profit: the tax line overwhelms operations

Continuing operations earned $14.148M at the operating line in Q2, down from $19.727M. Negative R&D means contract closeout adjustments more than offset current research charges; it is not a sustainable profit source. G&A quadrupled to $16.044M as separation and GSK/Tesaro litigation costs arrived alongside stock compensation.

Below operating income, the non-cash interest charge on sold royalties was $20.333M. That line is economically central. The company has received cash up front from Sagard and recognizes interest as the expected future payments accrete. A conventional price/earnings ratio would treat the tax benefit as earnings and the royalty financing as an ordinary interest expense, obscuring the fact that both are tied to balance-sheet and contract mechanics.

Q2 pretax loss was $4.174M. The $181.491M tax benefit then produced $177.317M of continuing income. Discontinued operations added $6.563M, yielding $183.880M of consolidated net income. This bridge makes clear why the $5.11 diluted EPS headline is not an earnings run rate.

Our valuation starts with expected cash that may reach the remaining owners after Sagard, corporate costs and tax. It gives no multiple to the one-time tax benefit.

Earnings quality: revenue is real, EPS is not repeatable

The strongest quality point is the royalty base. Jemperli sales grew 30.3% over the comparable half, and Anaptys recognized $53.044M of H1 collaboration revenue. That connects the income statement to a commercial product sold by a capable partner.

The weak quality point is the reported bottom line. H1 pretax loss was $5.093M. A $181.451M benefit transformed it into $176.358M of continuing income. Discontinued operations then lost $45.362M. Neither the tax release nor the spin-off loss describes the cash flow shareholders should expect from a mature royalty-management business.

Revenue concentration is extreme. Most near-term economics depend on one GSK collaboration, while that same contract is in litigation. G&A includes costs of defending the rights that support revenue. This makes the legal process an operating issue, not a footnote. On the other hand, the company no longer bears the former development portfolio's full expense burden after the spin-off, so continuing operating costs should be structurally lower than the historical consolidated cost base.

The quality score is mixed: commercially linked royalties are a strength; one-time tax accounting, sold future royalties and unresolved contract litigation reduce comparability. We present GAAP results exactly, then decline to capitalize the headline EPS.

Cash: use the audited bridge, not the release shorthand

June cash and cash equivalents were $133.826M; short-term investments added $30.317M, for $164.143M of cash and investments. Partner receivables were another $25.634M. Against that liquidity stand $35.353M of current liabilities, $256.493M of future-royalty liability, $3.619M of long-term taxes and $13.095M of lease obligations.

The press-release narrative says cash decreased mainly because $72.9M was used for operating activities, partly offset by $25.4M from option exercises. The audited cash-flow statement says continuing operations used $1.402M and discontinued operations used $51.157M, for a combined $52.559M. Those lines do not reconcile to the narrative. We therefore use the audited $52.559M in analysis and retain the $72.9M sentence only as an unresolved disclosure discrepancy.

Cash flow also includes a $100M financing outflow in discontinued operations tied to the separation and $42.545M of continuing-investing inflow. The $52.559M operating figure should not be converted into a clean annual burn rate without adjusting for one-time separation costs and the new continuing-business structure.

For valuation we calculate $112.076M of net liquid resources after current liabilities, leases and long-term taxes. We do not subtract the entire royalty liability and then also remove Sagard's future receipts from the forecast; that would count the same economic claim twice.

Valuation: price the royalties after Sagard

Our base case asks what post-Sagard cash could reach shareholders without assuming that Anaptys wins the litigation. The company expects approximately $299M of remaining Sagard paydown after Q2 and anticipates clearing it in the second half of 2027. We begin with only $40M of modeled 2027 shareholder royalty cash, then step to $180M in 2028, $260M in 2029, $330M in 2030 and a $390M peak from 2033 through 2034 before decline. These are Charged Alpha assumptions, not guidance.

Discounting those after-tax, after-corporate-cost cash flows at 12% produces $1,612.3M of present value. Adding $112.1M of net liquid resources and dividing by 29.728M shares gives $58.01 per share. There is no terminal value after 2037 and no value for a rights-reversion win. The model is intentionally finite because patents, competition and contract terms make a perpetual-growth formula inappropriate.

Two checks keep the DCF honest. A forward-sales/royalty-capacity approach yields $60.87; a transaction-and-consensus anchor yields $55.13. Those checks are not independent proof: all depend on Jemperli growth and the contract. Their rounded average supports a $58 base value.

The bear case is $25, the base $58 and the bull $95. Weighting them 30%, 50% and 20% gives $55.50. At $54.99, the stock trades 5.5% below the base and 0.9% below the weighted value. That is too little cushion for litigation and concentration risk. Our call is HOLD, 3 out of 5 conviction, with Very High uncertainty.

Wall Street versus this assessment

The provider's last-month target summary averages $74 across two observations. The newest records saved before this print include Wolfe Research at $78 on August 31 and a $70 report on August 25. The source labels the latter analyst company as Scotiabank even though the news title says TD Cowen, so this packet does not resolve the identity by guess. It preserves the source inconsistency.

Those targets imply more upside than our $58 base. They also predate the September 21 statements, the final audited transition figures and the latest litigation schedule. A target can still be analytically useful after a month, but it should not be labeled a post-print reaction.

The FMP consensus distribution lists 17 Buy and six Hold ratings with no sells. That breadth signals optimism, while the target dispersion signals uncertainty. Published targets are observations of other analysts' views, not independent cash flows. We do not average them into our DCF as if popularity reduced legal risk.

Our disagreement is narrow. We agree that Jemperli growth is valuable and that the Sagard paydown can create a step-up in shareholder cash. We demand a larger discount for one-contract concentration and a lawsuit in which Anaptys seeks reversion of the rights that generate the revenue. A favorable result could make our $58 too low. An adverse interpretation could reduce both the cash-flow value and the confidence investors place in the contract.

Management and capital allocation

Management completed the separation on April 20 and filed audited transition statements five months later. The 10-KT says all required periodic reports were filed and concludes disclosure controls and internal control over financial reporting were effective. That resolves the historical fiscal-calendar issue for current screening; it does not guarantee every narrative sentence is error-free, as the operating-cash discrepancy demonstrates.

The continuing company has a focused job: protect the GSK and Vanda economics, operate a limited-cost infrastructure and return value to shareholders. G&A of $23.390M in six months is not yet a settled run rate because it includes separation and litigation costs. Investors should grade the post-spin expense base after these events normalize.

The board authorized a $100M repurchase program in March, but no shares had been repurchased by June 30. At the same time, option exercises supplied $25.4M of financing cash and the diluted share count for Q2 reached 35.975M because of in-the-money awards. A buyback authorization is not capital return until shares are actually retired, and it should be evaluated against cash needed to defend the royalty contract.

EcoR1 beneficially owned 26.5% at June 30. Concentrated ownership can align a large investor with per-share value, while also concentrating governance influence. The practical scorecard is simple: maintain a lean expense base, avoid value-destructive capital use, disclose the Sagard bridge clearly and communicate the litigation without treating an expected judgment as a guaranteed victory.

Risks and the strongest opposing cases

The largest risk is litigation. Trial occurred July 14 through July 17. The parties' post-trial briefing continues through October, with a hearing scheduled October 20 and management expecting judgment in Q4 2026 or Q1 2027. Anaptys seeks enforcement of a reversion provision that would return dostarlimab rights. The April dismissal of Tesaro's breach counterclaim did not resolve the entire case.

A favorable rights reversion could create strategic value beyond the base DCF, but it could also impose new commercialization, licensing or transition decisions. An adverse outcome could leave the existing collaboration intact, weaken negotiating leverage or create other economic consequences. The base case adds no litigation-win value because the outcome and remedy are uncertain.

The second risk is concentration. Jemperli drives most near-term revenue, and GSK controls development and commercialization. Competition from Keytruda and other agents can change sales, pricing and market share. Patent and regulatory setbacks can change the duration or level of royalties. Even strong H1 growth does not eliminate that dependency.

The third risk is accounting and cash interpretation. Future royalties have already been sold to Sagard, tax benefits lifted EPS, and discontinued operations consumed cash during the separation. A screen can label the stock profitable while shareholders still wait for the cash stream. Finally, options, awards and repurchase decisions can change per-share value. The bear case allows for a material contraction below book-value-style shortcuts because the assets are contractual and the liabilities have priority.

A calendar of evidence

The next hard date is October 20, the scheduled post-trial hearing. It may not produce a same-day decision. The correct checkpoint is the court's actual order and remedy, not speculation around oral argument. We will separate a procedural update from a final judgment.

Vanda's Quimilza target action date is December 12, 2026. Approval would validate the regulatory package and may trigger commercial economics; rejection, delay or restrictive labeling would weaken the second royalty stream. The label and payment terms matter more than the yes-or-no headline.

GSK's Jemperli decision for rectal cancer carries a February 2027 PDUFA date, with potential earlier review under the National Priority Voucher program. First AZUR-1 data are scheduled for presentation October 25. The complete efficacy, duration and safety data should be read before changing the sales curve.

The company expects the remaining Sagard amount to pay down in H2 2027. Each quarterly royalty disclosure can grade that estimate. Annualized royalties payable to Anaptys could exceed $390M as early as 2029 at GSK's stated peak-sales ambition, but that is a scenario conditioned on sales and the contract. The next packet should update sales, royalties earned by Sagard, shares, cash and normalized G&A together.

Data, sources and reproducibility

The September 21 Exhibit 99.1 supplies the Q2/H1 comparison and current business update. The audited 10-KT supplies the transition-period balance sheet, cash flows, equity, notes, fiscal-calendar explanation and legal proceedings. When the release narrative and audited table differ, this packet uses the audited line items and identifies the discrepancy rather than blending the numbers.

All reported statement values are in U.S. dollars. Tables generally show millions; per-share values remain ordinary dollars. Parentheses denote losses or outflows. Continuing and discontinued operations stay separate until the statement itself combines them. The spin-off does not erase historical cash used by First Tracks, but it changes what is likely to recur in Anaptys.

Market information comes from dated FMP responses saved with hashes in market_sources.json. The close and target records are used within their dates. FMP's September 21 earnings actual is rejected because it conflicts with the primary statement. Its annual estimates are excluded from valuation because the current fiscal-year transition and one-time tax benefit make comparability fragile.

The explicit DCF can be reproduced from the eleven annual cash assumptions in data.json, a 12% discount rate, $112.076M of net liquid resources and 29.728M shares. It includes no terminal value and no litigation award. The sales and anchor checks are analyst judgments, labeled rather than disguised as issuer facts. Scenario probabilities describe investment cases, not measured court or regulatory probabilities.

Primary links: earnings release and audited transition report. Local source copies, SHA256 hashes and fetch times are retained with the episode.